Carboxyl-terminal  ||| S:0 E:18 ||| JJ
parathyroid  ||| S:18 E:30 ||| JJ
hormone  ||| S:30 E:38 ||| NN
fragments ||| S:38 E:47 ||| NNS
:  ||| S:47 E:49 ||| :
biologic  ||| S:49 E:58 ||| FW
effects  ||| S:58 E:66 ||| FW
Carboxyl-terminal  ||| S:66 E:84 ||| FW
PTH  ||| S:84 E:88 ||| FW
fragments  ||| S:88 E:98 ||| FW
( ||| S:98 E:99 ||| -LRB-
C-PTH ||| S:99 E:104 ||| NNP
) ||| S:104 E:105 ||| -RRB-
,  ||| S:105 E:107 ||| ,
are  ||| S:107 E:111 ||| VBP
generated  ||| S:111 E:121 ||| VBN
by  ||| S:121 E:124 ||| IN
both  ||| S:124 E:129 ||| DT
direct  ||| S:129 E:136 ||| JJ
secretion  ||| S:136 E:146 ||| NN
from  ||| S:146 E:151 ||| IN
parathyroids  ||| S:151 E:164 ||| NN
in  ||| S:164 E:167 ||| IN
relation  ||| S:167 E:176 ||| NN
to  ||| S:176 E:179 ||| TO
serum  ||| S:179 E:185 ||| VB
calcium  ||| S:185 E:193 ||| JJ
levels  ||| S:193 E:200 ||| NNS
and  ||| S:200 E:204 ||| CC
catabolism  ||| S:204 E:215 ||| NN
of  ||| S:215 E:218 ||| IN
PTH  ||| S:218 E:222 ||| NNP
operated  ||| S:222 E:231 ||| VBD
by  ||| S:231 E:234 ||| IN
the  ||| S:234 E:238 ||| DT
Kupffer  ||| S:238 E:246 ||| JJ
cells  ||| S:246 E:252 ||| NNS
in  ||| S:252 E:255 ||| IN
the  ||| S:255 E:259 ||| DT
liver ||| S:259 E:264 ||| NN
.  ||| S:264 E:266 ||| .
These  ||| S:266 E:272 ||| DT
molecular  ||| S:272 E:282 ||| JJ
fragments  ||| S:282 E:292 ||| NNS
have  ||| S:292 E:297 ||| VBP
been  ||| S:297 E:302 ||| VBN
till  ||| S:302 E:307 ||| IN
recently  ||| S:307 E:316 ||| RB
regarded  ||| S:316 E:325 ||| VBN
as  ||| S:325 E:328 ||| IN
inert  ||| S:328 E:334 ||| JJ
byproducts  ||| S:334 E:345 ||| NN
of  ||| S:345 E:348 ||| IN
PTH  ||| S:348 E:352 ||| NNP
metabolism ||| S:352 E:362 ||| NN
,  ||| S:362 E:364 ||| ,
since  ||| S:364 E:370 ||| IN
they  ||| S:370 E:375 ||| PRP
do  ||| S:375 E:378 ||| VBP
not  ||| S:378 E:382 ||| RB
interact  ||| S:382 E:391 ||| VBN
with  ||| S:391 E:396 ||| IN
the  ||| S:396 E:400 ||| DT
PTH ||| S:400 E:403 ||| FW
/ ||| S:403 E:404 ||| FW
PTH-related  ||| S:404 E:416 ||| FW
peptide  ||| S:416 E:424 ||| FW
( ||| S:424 E:425 ||| -LRB-
rP ||| S:425 E:427 ||| NNP
)  ||| S:427 E:429 ||| -RRB-
receptor ||| S:429 E:437 ||| NN
,  ||| S:437 E:439 ||| ,
which  ||| S:439 E:445 ||| WDT
mediates  ||| S:445 E:454 ||| VBZ
the  ||| S:454 E:458 ||| DT
classical  ||| S:458 E:468 ||| JJ
hormone  ||| S:468 E:476 ||| NN
actions ||| S:476 E:483 ||| NNS
.  ||| S:483 E:485 ||| .
Current  ||| S:485 E:493 ||| JJ
findings  ||| S:493 E:502 ||| NNS
instead  ||| S:502 E:510 ||| RB
indicate  ||| S:510 E:519 ||| VB
that  ||| S:519 E:524 ||| DT
C-PTH  ||| S:524 E:530 ||| NN
would  ||| S:530 E:536 ||| MD
interact  ||| S:536 E:545 ||| VB
with  ||| S:545 E:550 ||| IN
a  ||| S:550 E:552 ||| DT
putative  ||| S:552 E:561 ||| JJ
C-PTH  ||| S:561 E:567 ||| JJ
receptor ||| S:567 E:575 ||| NN
.  ||| S:575 E:577 ||| .
This  ||| S:577 E:582 ||| DT
way ||| S:582 E:585 ||| NN
,  ||| S:585 E:587 ||| ,
C-PTH  ||| S:587 E:593 ||| NNS
seem  ||| S:593 E:598 ||| VBP
to  ||| S:598 E:601 ||| TO
exert  ||| S:601 E:607 ||| VB
specific  ||| S:607 E:616 ||| JJ
effects  ||| S:616 E:624 ||| NNS
on  ||| S:624 E:627 ||| IN
calcium  ||| S:627 E:635 ||| JJ
homeostasis  ||| S:635 E:647 ||| NN
and  ||| S:647 E:651 ||| CC
bone  ||| S:651 E:656 ||| NN
metabolism ||| S:656 E:666 ||| NN
,  ||| S:666 E:668 ||| ,
opposite  ||| S:668 E:677 ||| JJ
to  ||| S:677 E:680 ||| TO
those  ||| S:680 E:686 ||| DT
of  ||| S:686 E:689 ||| IN
the  ||| S:689 E:693 ||| DT
synthetic  ||| S:693 E:703 ||| JJ
agonist  ||| S:703 E:711 ||| NN
of  ||| S:711 E:714 ||| IN
PTH ||| S:714 E:717 ||| NNP
/ ||| S:717 E:718 ||| NNP
PTHrP  ||| S:718 E:724 ||| JJ
receptor  ||| S:724 E:733 ||| NN
( ||| S:733 E:734 ||| -LRB-
i.e.  ||| S:734 E:739 ||| FW
PTH  ||| S:739 E:743 ||| FW
1-34 ||| S:743 E:747 ||| FW
) ||| S:747 E:748 ||| -RRB-
.  ||| S:748 E:750 ||| .
In  ||| S:750 E:753 ||| IN
vitro  ||| S:753 E:759 ||| NN
and  ||| S:759 E:763 ||| CC
in  ||| S:763 E:766 ||| IN
vivo  ||| S:766 E:771 ||| JJ
data  ||| S:771 E:776 ||| NNS
actually  ||| S:776 E:785 ||| RB
indicate  ||| S:785 E:794 ||| VB
that  ||| S:794 E:799 ||| DT
C-PTH ||| S:799 E:804 ||| JJ
,  ||| S:804 E:806 ||| ,
by  ||| S:806 E:809 ||| IN
interacting  ||| S:809 E:821 ||| NN
with  ||| S:821 E:826 ||| IN
specific  ||| S:826 E:835 ||| JJ
receptors ||| S:835 E:844 ||| NNS
,  ||| S:844 E:846 ||| ,
could  ||| S:846 E:852 ||| MD
have  ||| S:852 E:857 ||| VB
an  ||| S:857 E:860 ||| DT
anti-calcemic  ||| S:860 E:874 ||| JJ
action ||| S:874 E:880 ||| NN
,  ||| S:880 E:882 ||| ,
as  ||| S:882 E:885 ||| RB
well  ||| S:885 E:890 ||| RB
as  ||| S:890 E:893 ||| IN
a  ||| S:893 E:895 ||| DT
pro-apoptotic  ||| S:895 E:909 ||| JJ
effect  ||| S:909 E:916 ||| NN
on  ||| S:916 E:919 ||| IN
both  ||| S:919 E:924 ||| DT
osteocytes  ||| S:924 E:935 ||| NN
and  ||| S:935 E:939 ||| CC
osteoclasts ||| S:939 E:950 ||| NN
.  ||| S:950 E:952 ||| .
This  ||| S:952 E:957 ||| DT
in  ||| S:957 E:960 ||| IN
turn  ||| S:960 E:965 ||| NN
could  ||| S:965 E:971 ||| MD
result  ||| S:971 E:978 ||| VB
in  ||| S:978 E:981 ||| IN
a  ||| S:981 E:983 ||| DT
reduced  ||| S:983 E:991 ||| JJ
activity  ||| S:991 E:1000 ||| NN
of  ||| S:1000 E:1003 ||| IN
the  ||| S:1003 E:1007 ||| DT
latter  ||| S:1007 E:1014 ||| JJ
cells ||| S:1014 E:1019 ||| NNS
,  ||| S:1019 E:1021 ||| ,
with  ||| S:1021 E:1026 ||| IN
a  ||| S:1026 E:1028 ||| DT
consequent  ||| S:1028 E:1039 ||| JJ
inhibition  ||| S:1039 E:1050 ||| NN
of  ||| S:1050 E:1053 ||| IN
bone  ||| S:1053 E:1058 ||| NN
resorption ||| S:1058 E:1068 ||| NN
.  ||| S:1068 E:1070 ||| .
